# Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

> **NCT01740297** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 217 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Talimogene laherparepvec
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01740297
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-07
- **Primary completion:** 2016-08-23
- **Final completion:** 2021-03-09
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740297, "Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01740297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*